Melanoma research gets a funding boost from NHMRC
9 December 2016
Research projects led by Melanoma Institute Australia (MIA) have been awarded almost $6 million in the latest National Health and Medical Research Council (NHMRC) funding round which will enable vital progression of research into melanoma prevention and treatment. Projects led by MIA researchers have been awarded the highly competitive funding:
- Professor Georgina Long (MIA and The University of Sydney) received a Practitioner Fellowship (5 years) to investigate the underlying biology of patients’ responses to treatment. By understanding why some patients respond well to therapies when others develop resistance will help us develop tests to ensure the best possible treatment is given to each individual patient. In addition, it will also help identify the ideal drug therapy combinations to improve patient outcomes further or prevent metastatic melanoma altogether.
- Professor Nicholas Hayward (MIA and QIMR Berghofer) received a Research Fellowship (3 years) to investigate genetic predisposition to melanoma in the general population and predisposed families, and the genes involved in traits underlying melanoma development. He was also awarded a Project Grant (5 years) to conduct a comprehensive genetic analysis of acral melanoma to ultimately identify new drug targets to treat this disease. Although an uncommon subtype of melanoma, acral melanoma has a bad prognosis and has been poorly characterised at the molecular level.
- Professor Helen Rizos (MIA and Macquarie University) received two Project Grants to investigate the cell biology of melanoma. These project grants involved a team of chief investigators from MIA, who have collaborated on melanoma response and resistance for many years, including Professor Richard Kefford, Professor Georgina Long, Dr Matteo Carlino, Dr Alexander Menzies and Dr Xu Dong Zhang, and new collaborator Professor Barbara Fazekas de St Groth. The first Project Grant (4 years) will be used to investigate the mechanisms of response and resistance to combination immunotherapies in order to enhance the duration and rate of patient response. The second Project Grant (4 years) will use tumour samples of patients who have developed resistance to immunotherapies to determine the underlying mechanisms involved. This information will accelerate the identification of new combination therapies to improve patient outcomes.
- Associate Professor Anne Cust (MIA and The University of Sydney) was awarded a 4-year Project Grant to improve skin cancer prevention. Her research will evaluate whether they can improve skin cancer prevention behaviours by giving personalised information about melanoma genetic risk. They will also explore the psycho-social, ethical and economic implications of receiving this information, with the ultimate aim to positively influence the future of skin cancer prevention in Australia.
To date, the 2016 NHMRC Grant Application Round has resulted in the commitment of more than $703 million to fund health and medical research across Australia.
Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.